AR011160A1 - Uso de acido graso poliinsaturado, de fosfolipidos, colina para preparar medicamentos utiles para reducir la incidencia de la enterocolitis necrosante,para la produccion de una formulacion enteral y formulacion enteral mejorada - Google Patents

Uso de acido graso poliinsaturado, de fosfolipidos, colina para preparar medicamentos utiles para reducir la incidencia de la enterocolitis necrosante,para la produccion de una formulacion enteral y formulacion enteral mejorada

Info

Publication number
AR011160A1
AR011160A1 ARP980100780A ARP980100780A AR011160A1 AR 011160 A1 AR011160 A1 AR 011160A1 AR P980100780 A ARP980100780 A AR P980100780A AR P980100780 A ARP980100780 A AR P980100780A AR 011160 A1 AR011160 A1 AR 011160A1
Authority
AR
Argentina
Prior art keywords
incidence
phospholipids
choline
enteral formulation
fatty acid
Prior art date
Application number
ARP980100780A
Other languages
English (en)
Spanish (es)
Original Assignee
Abbott Lab
Univ Tennessee Res Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab, Univ Tennessee Res Corp filed Critical Abbott Lab
Publication of AR011160A1 publication Critical patent/AR011160A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
ARP980100780A 1997-02-21 1998-02-20 Uso de acido graso poliinsaturado, de fosfolipidos, colina para preparar medicamentos utiles para reducir la incidencia de la enterocolitis necrosante,para la produccion de una formulacion enteral y formulacion enteral mejorada AR011160A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80470097A 1997-02-21 1997-02-21
US82531497A 1997-03-28 1997-03-28
US08/943,576 US6080787A (en) 1997-02-21 1997-10-03 Methods for reducing the incidence of necrotizing enterocolitis

Publications (1)

Publication Number Publication Date
AR011160A1 true AR011160A1 (es) 2000-08-02

Family

ID=27122714

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100780A AR011160A1 (es) 1997-02-21 1998-02-20 Uso de acido graso poliinsaturado, de fosfolipidos, colina para preparar medicamentos utiles para reducir la incidencia de la enterocolitis necrosante,para la produccion de una formulacion enteral y formulacion enteral mejorada

Country Status (5)

Country Link
US (1) US6080787A (https=)
JP (1) JP2011137015A (https=)
KR (1) KR100439166B1 (https=)
AR (1) AR011160A1 (https=)
IL (1) IL150490A (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22723A1 (es) * 1997-04-02 2002-02-28 Dalmer Lab Sa Mezcla de ácidos grasos primarios de alto peso molecular obtenidos de la cera de cana de azúcar y sus usos farmacéuticos
EP1090636A1 (en) * 1999-09-13 2001-04-11 Société des Produits Nestlé S.A. High lipid diet
EP1181870A1 (en) * 2000-08-22 2002-02-27 Belovo Eggs & Egg Products Manufactured lipid emulsion having an improved balanced dietary source of vitamin F
CA2439293A1 (en) * 2001-03-05 2002-09-12 Stephen P. Ernest Enteral formulation
US6620427B2 (en) * 2001-04-24 2003-09-16 Abbott Laboratories Method for improving bone mineralization
AU2002309856B2 (en) * 2001-05-14 2008-10-23 Dsm Ip Assets B.V. Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms
CA2446059C (en) * 2001-05-14 2010-03-23 Dsm Ip Assets B.V. Production and use of a polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes
JP2003048831A (ja) * 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US20040013787A1 (en) * 2002-06-28 2004-01-22 Theuer Richard C. Fat compositions for infant formula and methods therefor
JP4771697B2 (ja) * 2002-09-24 2011-09-14 サントリーホールディングス株式会社 認知能力の正常応答の低下予防、改善又は向上作用を有する組成物
JP2006516614A (ja) * 2003-02-05 2006-07-06 エヌ．ブイ．・ヌートリシア 敗血症の予防および／または治療のための経腸組成物
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
CN1842277A (zh) * 2003-06-24 2006-10-04 堪萨斯大学医学中心 婴儿配方食品
FI20060154A7 (fi) 2003-08-18 2006-05-11 Btg Int Ltd Neurogeneratiivisten tilojen hoito
JP4522075B2 (ja) * 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP2006083136A (ja) * 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
EP1888081B1 (en) 2005-05-23 2016-12-28 Massachusetts Institute of Technology Compositions containing pufa and methods of use thereof
JP5967855B2 (ja) * 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
JP5697293B2 (ja) * 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
US7829126B2 (en) 2005-10-26 2010-11-09 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein
US20070166354A1 (en) * 2005-10-26 2007-07-19 Bridget Barrett-Reis Method of reducing the risk of retinopathy of prematurity in preterm infants
EP2098229A4 (en) * 2006-12-28 2010-03-10 Suntory Holdings Ltd NERVE REGENERATION MEDIUM
CA2688293A1 (en) 2007-05-25 2008-12-04 Childrens's Medical Center Corporation Dietary formulations and methods for treatment of inflammation and other disorders
CN101801200B (zh) * 2007-09-17 2014-10-29 康奈尔大学 用于预防或治疗胃肠病症的支链脂肪酸
EP2258216A1 (en) * 2009-06-02 2010-12-08 Nestec S.A. Nutritional Composition for Supporting Brain Development and Function of Toddlers
US20110200644A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Ester Emulsions
US20110206741A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation DHA Triglyceride Emulsions
US20110200645A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Free Fatty Acid Emulsions
MY196432A (en) 2010-12-31 2023-04-10 Abbott Lab Methods Of Using Human Milk Oligosaccharides For Improving Airway Respiratory Health
CA2822219C (en) 2010-12-31 2020-12-29 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
BR112013016587A2 (pt) 2010-12-31 2016-09-27 Abbott Lab formulações nutricionais incluindo oligossacarídeos de leite humano e antioxidantes e usos das mesmas
MY191538A (en) 2010-12-31 2022-06-30 Abbott Lab Human milk oligosaccharides to promote growth of beneficial bacteria
BR112013016903A2 (pt) 2010-12-31 2019-09-24 Abbott Lab oligossacarídeos de leite humano para modular inflamação
BR112013016606A2 (pt) 2010-12-31 2016-09-27 Abbott Lab processos para redução de incidência de tensão oxidante usando oligossacarídeos de leite humano, vitamina c e agentes antiflamatórios
DK2658399T4 (da) 2010-12-31 2024-03-25 Abbott Lab Ernæringssammensætninger omfattende humane mælkeoligosaccharider til anvendelse i behandling og/eller forebyggelse af enterisk rotavirus-infektion
PH12014500185A1 (en) 2011-07-22 2019-10-11 Abbott Lab Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
HK1199607A1 (en) 2011-08-29 2015-07-10 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
WO2014078544A1 (en) * 2012-11-14 2014-05-22 Abbott Laboratories Compositions and methods for improving the long term safety of powdered infant formulas
TW201440654A (zh) 2012-12-18 2014-11-01 Abbott Lab 含有低致敏蛋白質及葉黃素之液態濃縮人乳強化劑
EP3397078A1 (en) * 2015-12-28 2018-11-07 Abbott Laboratories Nutritional compositions comprising hydrolyzed protein and a modified fat system and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0092121B1 (en) * 1982-04-12 1987-12-16 Board Of Regents, The University Of Texas System Methods and compositions for treating gastro-intestinal ulcer diesease
US4670285A (en) * 1982-08-06 1987-06-02 The University Of Toronto Innovations Foundation Infant formula
US4784861A (en) * 1986-11-24 1988-11-15 Cca Industries, Inc. Weight-control formulation
US4918063A (en) * 1987-02-17 1990-04-17 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US5032585A (en) * 1987-02-17 1991-07-16 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy
US5043329A (en) * 1987-02-17 1991-08-27 Board Of Regents, University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US4950656A (en) * 1987-02-17 1990-08-21 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
DE3734147C2 (de) * 1987-10-09 1998-10-29 Braun Melsungen Ag Isotone omega-3-fettsäurenhaltige Fettemulsion und ihre Verwendung
US5000975A (en) * 1988-12-29 1991-03-19 American Home Products Corporation Randomized palm oil fat composition for infant formulas
US5658767A (en) * 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
CA2101274C (en) * 1991-01-24 1998-12-15 David J. Kyle Microbial oil mixtures and uses thereof
WO1993020717A2 (en) * 1992-04-13 1993-10-28 Research Corporation Technologies, Inc. Reducing gastrointestinal irritation in infant nutrition
FR2721481B1 (fr) * 1994-06-27 1996-09-06 Inst Rech Biolog Sa Nouvelles compositions diététiques à base de phospholipides et leur utilisation comme complément nutritionnel.
DK0784437T3 (da) * 1994-10-05 1999-04-19 Milupa Gmbh & Co Kg Phospholipidholdig fedtblanding med LCP-fedtsyrer
JPH09201A (ja) * 1995-06-23 1997-01-07 Akikuni Yakida 炎症性腸疾患用食品
US5917068A (en) * 1995-12-29 1999-06-29 Eastman Chemical Company Polyunsaturated fatty acid and fatty acid ester mixtures free of sterols and phosphorus compounds
US6200624B1 (en) * 1996-01-26 2001-03-13 Abbott Laboratories Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids

Also Published As

Publication number Publication date
KR100439166B1 (ko) 2004-07-07
KR20000075539A (ko) 2000-12-15
US6080787A (en) 2000-06-27
JP2011137015A (ja) 2011-07-14
IL150490A (en) 2007-05-15

Similar Documents

Publication Publication Date Title
AR011160A1 (es) Uso de acido graso poliinsaturado, de fosfolipidos, colina para preparar medicamentos utiles para reducir la incidencia de la enterocolitis necrosante,para la produccion de una formulacion enteral y formulacion enteral mejorada
AR005556A1 (es) Formula enteral, un suplemento nutricional que contiene una composicion de trigliceridos, trigliceridos, y un procedimiento para preparar esteres de acidos grasos a partir de una mezcla de lipidos
IL131126A (en) Compositions for reducing the incidence of necrotizing enterocolitis and the preparation thereof
AU613420B2 (en) Dietary supplement utilizing omega-3/medium chain triglyceride mixtures
CL2009000799A1 (es) Composicion de alimento materno que comprende una fuente de lipidos donde los lipidos incluyen al menos un acido graso poliinsaturado de cadena larga seleccionado de: fosfolipidos, fosfatidilcolina, fosfatidiletanolamina, n-acilfosfatidiletanolamina, fosfatidilinositol, fosfatidilserina y/o sus liso derivados; usos.
Sugino et al. Antioxidative activity of egg yolk phospholipids
GB2084172A (en) Lipid compositions useful in dietetics
EP1072249A3 (de) Kosmetische und dermatologische Zubereitungen auf der Grundlage von O/W-Emulsionen
RU2005120159A (ru) Водорастворимые концентраты эмульсионного типа
KR970002608B1 (ko) 감마-리놀렌산과 칼슘을 함유하는 치료학적 조성물
IT9021610A1 (it) Composizioni per il trattamento della pelle contenenti derivati della b-fosfatidilcolina
US6251425B1 (en) Glucoside paucilamellar vesicles
JP2004505904A (ja) 化粧品において脂質成分として使用する皮脂用調整物
CA2207325A1 (en) Anti-oxidant compositions
JP3081226B2 (ja) 脂肪又は脂肪含有製品の酸化防止方法
JPH0366616A (ja) 脂肪酸の薬学的およびダイエット的用途
Galli et al. Modulation of lipid derived mediators by polyunsaturated fatty acids
Noble et al. The liver phospholipids of the developing chick embryo
JPH07503014A (ja) 癌の治療におけるカロチノイド類の処方及び用法
Jannace et al. Effects of oral soy phosphatidylcholine on phagocytosis, arachidonate concentrations, and killing by human polymorphonuclear leukocytes
JP2514995B2 (ja) 経皮、経粘膜による物質の吸収を促進する組成物
Koletzko et al. Fatty acid composition of plasma lipids in acrodermatitis enteropathica before and after zinc supplementation
Ishinaga et al. Perturbation of phospholipid metabolism by erucic acid in male Sprague-Dawley rat heart
Lewis Lipid composition of human bronchial mucus
Señoráns et al. Formulations based on milk fat globule membrane as delivery systems for DHA and lutein: effects on lipid composition and immunomodulatory properties

Legal Events

Date Code Title Description
FB Suspension of granting procedure